A Chinese-owned company has defeated a billion-dollar claim over the supply of masks during the covid-19 pandemic to a US company, which failed to disclose it intended to resell the equipment.
18 March 2025
The administrator of a German construction holding company has brought an ICSID claim against Algeria.
17 March 2025
The Court of Appeal in London is being urged to restrain “pre-emptive” recognition proceedings in Pakistan brought by an LCIA award debtor that is seeking to have parts of the award declared unenforceable.
17 March 2025
An ICSID tribunal has refused to summarily dismiss a US$150 million claim brought against Georgia by a former minister who obtained political asylum in the US, finding that the state’s objections raised “novel, difficult and complex” issues about his nationality and investments.
14 March 2025
An ICDR emergency arbitrator has restrained a former employee of Meta from promoting a whistleblowing memoir of her time at Facebook while the company pursues a claim against her for breach of a non-disparagement clause.
13 March 2025
An American publisher of academic journals has sought an injunction against European publishing giant Springer Nature to prevent “dishonest sales tactics” ahead of a New York arbitration over alleged breach of distribution agreements.
13 March 2025
A Swiss court has upheld an UNCITRAL tribunal’s decision to dismiss a US$200 million investment treaty claim against Venezuela because the claimant’s dominant and effective nationality was Venezuelan rather than Spanish.
12 March 2025
An ICSID annulment committee has upheld an award that threw out a US$235 million damages claim against the Czech Republic over a residential development even though the state was found liable.
11 March 2025
Guyana and a US-Puerto Rican contractor have agreed to send their dispute over the delayed construction of a US$759 million power plant to ICC arbitration.
07 March 2025
A US pharmaceutical company has asked an ICC emergency arbitrator to halt its Taiwanese partner’s development of a drug to treat a rare neuromuscular disease – a dispute arising from a US$250 million licensing deal.
06 March 2025
Unlock unlimited access to all Global Arbitration Review content